• Jingsong Wang, MD, PhD

    Founder, Chairman and Chief Executive Officer

    Dr. Wang is the CEO of Harbour Biomed (HBM). Before establishing HBM, Dr. Wang served as the Head of China Research and Development Center and the Head of Translational Medicine for Asia Pacific at Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served in multiple roles with increasing responsibilities, including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for multiple pre-clinical and clinical assets.
    Dr. Wang completed his Clinical Rheumatology Fellowship and subsequently was an Attending Rheumatologist and faculty member at Brigham and Women's Hospital and Harvard Medical School. Dr. Wang received his PhD in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher's laboratory at the Harvard School of Public Health.
    Dr. Wang is an Adjunct Assistant Professor of Medicine at the University of Pennsylvania. He has served on the Research Grant Review Committee, National Natural Science Foundation of China, and as a scientific grant reviewer for the Medical Research Council, National Institute for Health Research, National Health Service of the United Kingdom.
  • Atul Deshpande, PhD MBA

    Chief Strategy Officer & Head, US Operations

    Dr. Deshpande brings to HBM an extensive background in immunology, neuroscience and other therapeutic areas and across the pharmaceutical value chain, including both strategy and execution. He joined HBM from Sanofi in January 2019, where he served as Global Operations Lead of Sanofi Genzyme's Dupixent® (dupilumab) franchise. During his tenure at Sanofi Genzyme, Dr. Deshpande delivered on roles with increasing responsibility from strategy to implementation. He was instrumental in establishing and executing global launches for Dupixent in Atopic Dermatitis and Asthma, a blockbuster brand in the making. He also served as head of Asia Pacific R&D Strategy at Sanofi. Prior to Sanofi Genzyme, Dr. Deshpande served at several life science strategic consulting firms.
    Dr. Deshpande holds a Ph.D. in Neurobiology and Behavior from University of California, Irvine and an MBA from Cranfield University (UK).
  • Xiaoxiang Chen, MD

    Chief Development Officer

    Dr. Chen brings to HBM more than 20 years of leadership experience in global and regional clinical development, most recently as Boehringer Ingelheim's Vice President, Regional Medical Management for Emerging Markets. In this role, Dr. Chen had overall medical responsibilities, including clinical development, in more than 80 countries and regions, including China, Taiwan, Hong Kong, South Eastern Asia, India, the Middle East and Africa. Prior to Boehringer Ingelheim, Dr. Chen served as Director, Clinical Research & Development with Wyeth Asia Pacific, and Global Medical Monitor for chronic pain and infections.
    During his career, Dr. Chen has led the successful clinical development and registration of more than 20 global innovative products across multiple therapeutic areas, including etanercept, tigecycline, venlafaxine, afatinib, nintedanib, dabigatran, linagliptin and empagliflozin into China. Dr. Chen received his Medical Degree from Nanjing Medical University.
  • Mai-Jing Liao, PhD, MBA

    Chief Business Officer

    Dr. Mai-Jing Liao brings to HBM more than 12 years of Marketing and Business Development experience. Prior to joining HBM, Dr. Liao was at Xian Janssen Pharmaceutical Ltd. where he served in multiple roles with increasing responsibilities in Marketing, Strategic Marketing and Business Development. He joined J&J's Centocor US subsidiary after receiving his MBA degree from Johnson Graduate School of Management at Cornell University.
    Dr. Liao received his PhD degree in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill and was a postdoctoral fellow in Dr. Robert Weinberg's laboratory at Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology (MIT).
  • Louis Liu, MD

    Senior Vice President, Head of Technology Platform

    Dr. Liu brings more than 30 years of industry experience in biotech industry focusing on antibody discovery and assay development and validation. Prior to joining Harbour, Dr. Liu served as the Executive Director and Vice President of Biologics Discovery at ChemPartner since 2010. Previously, he was the Vice President, Antibody Division, GenScript started in 2006. Dr. Liu also worked at various US based biotech companies including Rockland Immunochemicals, Strategic Diagnostics, Syntron Bioresearch. He also served as a faculty member at the Chinese Academy of Medical Sciences.
    Dr. Liu received his MD from the Norman Bethune Medical University in China.
  • Yiping Rong, PhD

    Head of Discovery Biology

    Dr. Rong brings to HBM an extensive background in oncology drug discovery. He joined HBM from Sanofi, where he was Associate Director of Cancer Research at Sanofi Asia Pacific R&D Center. Prior to Sanofi, he served at the Johnson & Johnson China Discovery Center, where he was the Group Leader for preclinical translational oncology research, studying cell growth factor signaling pathway and epigenetic regulation in liver cancer. As the biology lead, he successfully generated the preclinical data package and patient stratification biomarker strategy to support novel oncology drug IND filings. Previously, Dr. Rong worked at Roche R&D as a group leader for a biologics Discovery in the Oncology Department. He was also involved in external project evaluation and coordination.
    Dr. Rong obtained his PhD in Pharmacology from Case Western Reserve University.
友情链接:w66利来老牌平台  利来资源站  腾博会娱乐  ag平台下载  ag环亚集团国际厅  白菜网免费送彩金  澳门葡京赌场官网  金博宝app